Business Highlights and Upcoming Milestones (GlobeNewswire) - Dec 4, 2025 - "Topline results from Phase 2 VISTA trial for ADP expected in the second half of 2027...The Company expects to complete IND-enabling studies for ML-021 in the second half of 2026."
P2 data • Preclinical • Alzheimer's Disease • Parkinson's Disease
|